Credit Suisse Ag Sarepta Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 176,136 shares of SRPT stock, worth $27.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

176,136

Previous 167,737 5.01%

Holding current value

$27.2 Million

Previous $16.2 Million 40.98%

% of portfolio

0.02%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$93.7 - $141.53 $786,986 - $1.19 Million	8,399 Added 5.01%	176,136 $22.8 Million
Q4 2023 Feb 08, 2024	BUY	$67.31 - $124.76 $1.87 Million - $3.47 Million	27,838 Added 19.9%	167,737 $16.2 Million
Q3 2023 Nov 13, 2023	SELL	$102.5 - $123.59 $8.71 Million - $10.5 Million	-84,932 Reduced 37.78%	139,899 $17 Million
Q2 2023 Aug 11, 2023	BUY	$106.4 - $157.19 $3.37 Million - $4.98 Million	31,659 Added 16.39%	224,831 $25.7 Million
Q1 2023 May 10, 2023	SELL	$117.53 - $155.99 $9.7 Million - $12.9 Million	-82,507 Reduced 29.93%	193,172 $26.6 Million

Q4 2022 Feb 13, 2023	SELL	$100.86 - $132.13 $1.17 Million - $1.53 Million	-11,552 Reduced 4.02%	275,679 $35.7 Million
Q3 2022 Nov 10, 2022	SELL	$75.71 - $119.24 $9.1 Million - $14.3 Million	-120,209 Reduced 29.5%	287,231 $31.8 Million
Q2 2022 Aug 12, 2022	SELL	$62.69 - $88.44 $12 Million - $16.9 Million	-190,722 Reduced 31.88%	407,440 $30.5 Million
Q1 2022 May 16, 2022	SELL	$63.15 - $90.42 $14.7 Million - $21.1 Million	-233,036 Reduced 28.04%	598,162 $46.7 Million
Q4 2021 Feb 14, 2022	SELL	$77.28 - $99.42 $380,758 - $489,842	-4,927 Reduced 0.59%	831,198 $74.8 Million
Q3 2021 Nov 12, 2021	BUY	$65.97 - $92.48 $13.2 Million - $18.5 Million	199,721 Added 31.38%	836,125 $77.3 Million
Q2 2021 Aug 16, 2021	BUY	$69.38 - $86.75 $2.12 Million - $2.65 Million	30,554 Added 5.04%	636,404 $49.5 Million
Q1 2021 May 14, 2021	BUY	$72.25 - $168.95 $9.54 Million - $22.3 Million	132,009 Added 27.86%	605,850 $45.2 Million
Q4 2020 Feb 12, 2021	BUY	$125.56 - $178.74 $8.76 Million - $12.5 Million	69,756 Added 17.26%	473,841 $80.8 Million
Q3 2020 Nov 13, 2020	BUY	$127.12 - $172.34 $220,680 - $299,182	1,736 Added 0.43%	404,085 $56.7 Million
Q2 2020 Aug 12, 2020	BUY	$93.0 - $171.7 $758,601 - $1.4 Million	8,157 Added 2.07%	402,349 $64.5 Million
Q1 2020 May 13, 2020	SELL	$82.38 - $131.64 $1.81 Million - $2.89 Million	-21,979 Reduced 5.28%	394,192 $38.6 Million
Q4 2019 Feb 12, 2020	BUY	$76.53 - $135.58 $5.78 Million - $10.2 Million	75,541 Added 22.18%	416,171 $53.7 Million
Q3 2019 Nov 12, 2019	BUY	$72.81 - $156.91 $4.86 Million - $10.5 Million	66,697 Added 24.35%	340,630 $25.7 Million
Q2 2019 Aug 14, 2019	BUY	$112.21 - $151.95 $3.54 Million - $4.8 Million	31,581 Added 13.03%	273,933 $41.6 Million
Q1 2019 May 14, 2019	BUY	$106.67 - $151.68 $1.7 Million - $2.42 Million	15,963 Added 7.05%	242,352 $28.9 Million
Q4 2018 Feb 13, 2019	SELL	$97.32 - $148.76 $831,891 - $1.27 Million	-8,548 Reduced 3.64%	226,389 $24.7 Million
Q3 2018 Nov 13, 2018	BUY	$115.31 - $161.51 $4.92 Million - $6.89 Million	42,681 Added 22.2%	234,937 $37.9 Million
Q2 2018 Aug 14, 2018	SELL	$71.74 - $153.69 $13.8 Million - $29.6 Million	-192,475 Reduced 50.03%	192,256 $25.4 Million
Q1 2018 May 15, 2018	BUY	$54.02 - $82.27 $8.9 Million - $13.6 Million	164,778 Added 74.92%	384,731 $28.5 Million
Q4 2017 Feb 14, 2018	BUY	$47.64 - $56.75 $6.34 Million - $7.55 Million	133,001 Added 152.96%	219,953 $12.2 Million
Q3 2017 Nov 14, 2017	SELL	$35.73 - $47.15 $118,159 - $155,925	-3,307 Reduced 3.66%	86,952 $3.94 Million
Q2 2017 Aug 14, 2017	BUY	N/A	90,259	90,259 $3.04 Million

Others Institutions Holding SRPT

# of Institutions

470

Shares Held

79.3M

Call Options Held

4.23M

Put Options Held

1.21M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $13.5B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account